US Stock MarketDetailed Quotes
IMMP Immutep
- 2.160
- +0.170+8.54%
Close Aug 14 16:00 ET
- 2.060
- -0.100-4.63%
Post 19:59 ET
313.76MMarket Cap-8404P/E (TTM)
2.180High2.055Low326.39KVolume2.060Open1.990Pre Close695.17KTurnover0.26%Turnover RatioLossP/E (Static)145.26MShares3.33552wk High4.11P/B273.96MFloat Cap1.58052wk Low--Dividend TTM126.84MShs Float7.950Historical High--Div YieldTTM6.28%Amplitude0.530Historical Low2.129Avg Price1Lot Size
About Immutep Company
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Company Profile
SymbolIMMP
Company NameImmutep
Listing DateApr 16, 2012
Founded1987
CEOMr. Marc Voigt
MarketNASDAQ
Employees24
Securities TypeDR
ADS Ratio1.0 : 10.0
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32, Suite 32.07
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003
Websitehttp://www.immutep.com
Company Executives
- Name
- Position
- Salary
- Marc Voigt
- Director, Chief Executive Officer, Chief Financial Officer and Managing Director
- 1.11M
- Dr. Frederic Triebel, M.D.,PhD
- Director and Chief Scientific Officer
- 744.24K
- Deanne Miller
- Chief Operating Officer, General Counsel and Company Secretary
- 595.80K
- Pete A. Meyers
- Deputy Chairman of the Board
- 192.28K
- Dr. Russell J. Howard, PhD
- Non-Executive Chairman of the Board
- 171.99K
- Lis Boyce
- Independent Director
- 62.32K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg